PepGen Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di PepGen sono diminuiti a un tasso annuo medio di -44.4%, mentre il settore Biotechs ha visto gli utili crescere a un tasso annuo di 19.3%.

Informazioni chiave

-44.4%

Tasso di crescita degli utili

29.0%

Tasso di crescita dell'EPS

Biotechs Crescita del settore	17.0%
Tasso di crescita dei ricavi	n/a
Rendimento del capitale proprio	-63.5%
Margine netto	n/a
Ultimo aggiornamento sui guadagni	30 Sep 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Here's Why We're Watching PepGen's (NASDAQ:PEPG) Cash Burn Situation

Nov 19

PepGen (NASDAQ:PEPG) Is In A Good Position To Deliver On Growth Plans

Aug 06

PepGen: EDOs Could Enhance Dystrophin Expression Beyond Scope Of Current Treatments

Jul 31

Here's Why We're Not Too Worried About PepGen's (NASDAQ:PEPG) Cash Burn Situation

Sep 07

PepGen GAAP EPS of -$1.23 misses by $0.47

Aug 12

Ripartizione dei ricavi e delle spese

Come PepGen guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

NasdaqGS:PEPG Ricavi, spese e utili (USD Millions )
Data	Guadagni	Spese G+A	Spese di R&S
30 Sep 24	-87	20	74
30 Jun 24	-89	19	77
31 Mar 24	-80	18	68
31 Dec 23	-79	17	68
30 Sep 23	-74	16	65
30 Jun 23	-69	16	60
31 Mar 23	-67	15	58
31 Dec 22	-69	14	54
30 Sep 22	-61	13	45
30 Jun 22	-51	12	35
31 Mar 22	-39	10	24
31 Dec 21	-27	8	19
30 Sep 21	-23	6	15
30 Jun 21	-15	4	9
31 Mar 21	-10	2	6
31 Dec 20	-4	1	1

Guadagni di qualità: PEPG al momento non è redditizia.

Margine di profitto in crescita: PEPG al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: PEPG non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 44.4% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di PEPG nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: PEPG non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( 16.6% ).

Rendimento del capitale proprio

ROE elevato: PEPG ha un Return on Equity negativo ( -63.46% ), in quanto al momento non è redditizio.

PepGen Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

PepGen Inc. to Report Q1, 2023 Results on May 11, 2023

Recent updates

Here's Why We're Watching PepGen's (NASDAQ:PEPG) Cash Burn Situation

Price target decreased by 13% to US$17.00

New major risk - Revenue and earnings growth

PepGen Inc. Announces Christopher Ashton to Retire from Its Board of Directors, Effective September 30, 2024

New major risk - Share price stability

PepGen Inc. Appoints Paul Streck as Executive Vice President, Head of Research & Development, Head of Research & Development

Price target decreased by 9.3% to US$19.60

PepGen (NASDAQ:PEPG) Is In A Good Position To Deliver On Growth Plans

Chief Medical Officer exercised options and sold US$61k worth of stock

PepGen: EDOs Could Enhance Dystrophin Expression Beyond Scope Of Current Treatments

PepGen Inc. Announces Positive Data from Low-Dose Cohort of Pgn-Edo51 in Ongoing Connect1-Edo51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy

Chief Medical Officer exercised options and sold US$72k worth of stock

PepGen Inc. Appoints Afsaneh Mohebbi as SVP, Portfolio and Program Management and Dave Borah as SVP, Investor Relations and Corporate Communications

Chief Medical Officer exercised options and sold US$74k worth of stock

Pepgen Inc. Announces Executive Promotions

Insider notifies of intention to sell stock

The Prognosis For PepGen

Senior Vice President of Chemistry notifies of intention to sell stock

PepGen Inc., Annual General Meeting, Jun 20, 2024

PepGen Inc., Annual General Meeting, Jun 20, 2024

PepGen Inc. Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

PepGen Inc. Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1

PepGen Inc. has completed a Follow-on Equity Offering in the amount of $80.08155 million.

New minor risk - Shareholder dilution

New major risk - Share price stability

Price target decreased by 14% to US$20.00

PepGen: Long Road Ahead

Mary Beth DeLena Joins PepGen as General Counsel and Secretary

Pepgen Inc. Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of P GN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping

Pepgen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

Pepgen Announces First Patient Dosed in Phase 1 Freedom-Dm1 Clinical Trial of Pgn-Edodm1 for Myotonic Dystrophy Type 1

PepGen Inc. Announces Appointment of Howard Mayer, M.D. to Board of Directors

Will PepGen (NASDAQ:PEPG) Spend Its Cash Wisely?

New major risk - Revenue and earnings growth

PepGen Inc. Announces FDA Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company's Enhanced Delivery Oligonucleotide Platform and PGN-EDO Program at Two Medical Conferences

New major risk - Share price stability

New major risk - Revenue and earnings growth

Will PepGen (NASDAQ:PEPG) Spend Its Cash Wisely?

PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1

New major risk - Share price stability

Pepgen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate A Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1

PepGen Inc. to Report Q1, 2023 Results on May 11, 2023

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

Key Executive notifies of intention to sell stock

We Think PepGen (NASDAQ:PEPG) Can Afford To Drive Business Growth

PepGen Inc. Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies

High number of new and inexperienced directors

PepGen Inc. Announces Positive Preclinical Data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, Three Novel Duchenne Muscular Dystrophy Candidates

PepGen Inc. Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

PepGen Appoints Habib Dable to Board of Directors

Here's Why We're Not Too Worried About PepGen's (NASDAQ:PEPG) Cash Burn Situation

PepGen GAAP EPS of -$1.23 misses by $0.47

PepGen Inc. Appoints Caroline Godfrey to Its Scientific Advisory Board

PepGen Inc. has completed an IPO in the amount of $108 million.

High number of new and inexperienced directors

Ripartizione dei ricavi e delle spese

Storia dei guadagni e delle entrate

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Rendimento del capitale proprio

Rendimento delle attività

Rendimento del capitale investito

Scoprire le aziende con forti performance passate